Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | MPO | P05164 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378991 | 0.95 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2379635 | 0.94 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL664283 | 0.92 | MAPT (0.70) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29053759 | 0.90 | MAPT (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29363142 | 0.87 | MEN1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL27551570 | 0.87 | MEN1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29608427 | 0.87 | MEN1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL35884 | 0.87 | MEN1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL1520294 | 0.86 | MEN1 (0.63) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL10344942 | 0.86 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-4411684-A | Auxin compositions of N-phenyl and N-chloro phenyl indolyl-3-alkylene amides and their use as auxin growth regulators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1983-10-25 | — | — | US | claimed |
| US-12018092-B2 | Covalent heterobivalent antibody inhibitors and ligands | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-06-25 | — | — | US | disclosed |
| CN-113943244-A | Sulfur-containing gamma, gamma-diindolyl butyramide compound prepared by double-functionalization reaction | 温州大学 | 2022-01-18 | — | — | CN | disclosed |
| US-20210353763-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-18 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210115157-A1 | COVALENT HETEROBIVALENT ANTIBODY INHIBITORS AND LIGANDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10588982-B2 | Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180140715-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-24 | — | — | US | disclosed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| US-6291683-B1 | AS ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORP | 2001-09-18 | — | — | US | disclosed |
| EP-1070050-A1 | N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6121307-A | SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT DEPRESSION | AMERICAN HOME PRODUCTS CORP. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999051575-A1 | N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0376607-B1 | Piperazinyl derivatives | LUNDBECK & CO AS H (DK) | 1994-03-02 | — | — | EP | disclosed |
| US-5002948-A | Central Nervous System Disorders | H. LUNDBECK A/S (DK) | 1991-03-26 | — | — | US | disclosed |
| EP-0376607-A1 | Piperazinyl derivatives | H. LUNDBECK A/S (DK) | 1990-07-04 | — | — | EP | disclosed |
| US-4411684-A | Auxin compositions of N-phenyl and N-chloro phenyl indolyl-3-alkylene amides and their use as auxin growth regulators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140715-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | FCGR3B, FCGR2A, FCGR1A | ALDH1A1 1754/4885MEN1 4023/4885KMT2A 662/4885 |
| US-12018092-B2 | Covalent heterobivalent antibody inhibitors and ligands | BTD, DBI, FCER2 | ALDH1A1 4563/4885MEN1 3537/4885KMT2A 803/4885 |
| US-20210353763-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | FCGR3B, FCGR2A, FCGR1A | ALDH1A1 1754/4885MEN1 4023/4885KMT2A 662/4885 |
| US-10588982-B2 | Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin | FCGR3B, FCGR2A, FCGR1A | ALDH1A1 1754/4885MEN1 4023/4885KMT2A 662/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | ALDH1A1 2482/4885MEN1 2870/4885KMT2A 2312/4885 |
| US-20210115157-A1 | COVALENT HETEROBIVALENT ANTIBODY INHIBITORS AND LIGANDS | BTD, DBI, FCER2 | ALDH1A1 4563/4885MEN1 3537/4885KMT2A 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.